» Articles » PMID: 36830722

Reactive Oxygen Species and NRF2 Signaling, Friends or Foes in Cancer?

Overview
Journal Biomolecules
Publisher MDPI
Date 2023 Feb 25
PMID 36830722
Authors
Affiliations
Soon will be listed here.
Abstract

The imbalance between reactive oxygen species (ROS) production and clearance causes oxidative stress and ROS, which play a central role in regulating cell and tissue physiology and pathology. Contingent upon concentration, ROS influence cancer development in contradictory ways, either stimulating cancer survival and growth or causing cell death. Cells developed evolutionarily conserved programs to sense and adapt redox the fluctuations to regulate ROS as either signaling molecules or toxic insults. The transcription factor nuclear factor erythroid 2-related factor 2 (NRF2)-KEAP1 system is the master regulator of cellular redox and metabolic homeostasis. NRF2 has Janus-like roles in carcinogenesis and cancer development. Short-term NRF2 activation suppresses tissue injury, inflammation, and cancer initiation. However, cancer cells often exhibit constitutive NRF2 activation due to genetic mutations or oncogenic signaling, conferring advantages for cancer cells' survival and growth. Emerging evidence suggests that NRF2 hyperactivation, as an adaptive cancer phenotype under stressful tumor environments, regulates all hallmarks of cancer. In this review, we summarized the source of ROS, regulation of ROS signaling, and cellular sensors for ROS and oxygen (O), we reviewed recent progress on the regulation of ROS generation and NRF2 signaling with a focus on the new functions of NRF2 in cancer development that reach beyond what we originally envisioned, including regulation of cancer metabolism, autophagy, macropinocytosis, unfolded protein response, proteostasis, and circadian rhythm, which, together with anti-oxidant and drug detoxification enzymes, contributes to cancer development, metastasis, and anticancer therapy resistance.

Citing Articles

Protective Effects of Oleanolic Acid on Human Keratinocytes: A Defense Against Exogenous Damage.

Vasarri M, Bergonzi M, Leri M, Castellacci R, Bucciantini M, De Marchi L Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006051 PMC: 11859478. DOI: 10.3390/ph18020238.


Evidence for a Functional Link Between the Nrf2 Signalling Pathway and Cytoprotective Effect of S-Petasin in Human Retinal Pigment Epithelium Cells Exposed to Oxidative Stress.

Pizzoferrato M, Lazzarino G, Brancato A, Tabolacci E, Clementi M, Tringali G Antioxidants (Basel). 2025; 14(2).

PMID: 40002367 PMC: 11851853. DOI: 10.3390/antiox14020180.


Licochalcone A Induces Uterine Leiomyoma Cell Apoptosis via the ROS-Mediated JNK Activation of the GRP78/NRF2 Pathway In Vitro and In Vivo.

Chien H, Hu H, Tsai S, Lin C, Yang S, Chen J Antioxidants (Basel). 2025; 14(2).

PMID: 40002335 PMC: 11851460. DOI: 10.3390/antiox14020148.


Suppression of Spry1 reduces HIF1α-dependent glycolysis and impairs angiogenesis in BRAF-mutant cutaneous melanoma.

Montico B, Giurato G, Guerrieri R, Colizzi F, Salvati A, Nassa G J Exp Clin Cancer Res. 2025; 44(1):53.

PMID: 39953610 PMC: 11827140. DOI: 10.1186/s13046-025-03289-8.


A Sensitive and Reusable Phenothiazine-Benzophenone Based Fluorescence Probe for Detecting Hypochlorite in Environmental and Biological Systems.

Dhandapani V, Karpagam S J Fluoresc. 2025; .

PMID: 39792313 DOI: 10.1007/s10895-024-04110-z.


References
1.
Shafi A, Knudsen K . Cancer and the Circadian Clock. Cancer Res. 2019; 79(15):3806-3814. PMC: 8121183. DOI: 10.1158/0008-5472.CAN-19-0566. View

2.
Harris I, DeNicola G . The Complex Interplay between Antioxidants and ROS in Cancer. Trends Cell Biol. 2020; 30(6):440-451. DOI: 10.1016/j.tcb.2020.03.002. View

3.
Wang H, Liu K, Geng M, Gao P, Wu X, Hai Y . RXRα inhibits the NRF2-ARE signaling pathway through a direct interaction with the Neh7 domain of NRF2. Cancer Res. 2013; 73(10):3097-108. DOI: 10.1158/0008-5472.CAN-12-3386. View

4.
Nioi P, Nguyen T . A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem Biophys Res Commun. 2007; 362(4):816-21. DOI: 10.1016/j.bbrc.2007.08.051. View

5.
Shakhparonov M, Antipova N, Shender V, Shnaider P, Arapidi G, Pestov N . Expression and Intracellular Localization of Paraoxonase 2 in Different Types of Malignancies. Acta Naturae. 2018; 10(3):92-99. PMC: 6209399. View